ANI Pharmaceuticals (ANIP) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Septerna (SEPN) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 71.3% versus a loss of 21.5%. Septerna is the larger company by market cap ($1.72 billion vs $1.65 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | SEPN |
|---|---|---|
| Share price | $71.98 | $36.90 |
| Market cap | $1.65B | $1.72B |
| 1-day change | +0.07% | +2.50% |
| YTD return | -8.88% | +29.12% |
| 1-year return | -21.54% | +71.35% |
| 5-year return | +86.64% | — |
| P/E ratio (TTM) | 15.58 | — |
| Forward P/E | 7.08 | — |
| EPS (TTM) | $4.62 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.00 | $51.10 |
| 52-week low | $69.58 | $17.55 |
| Distance from 52-week high | -25.79% | -27.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.96% | +46.94% |
| Average volume | 372.56K | 393.97K |
| Shares outstanding | 22.96M | 46.68M |
| Employees | 970 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed ANIP by 92.9 percentage points over the past year.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
ANIP vs SEPN FAQ
Which is bigger, ANI Pharmaceuticals or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.72B compared with $1.65B for ANI Pharmaceuticals (ANIP).
Which stock has performed better over the past year, ANIP or SEPN?
SEPN returned +71.35% over the past 12 months, compared with -21.54% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.